CRISPR Therapeutics AG (CRSP) Depreciation & Amortization (CF) (2015 - 2026)

CRISPR Therapeutics AG has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $4.3 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) fell 7.94% year-over-year to $4.3 million; the TTM figure through Jun 2026 stood at $18.7 million (down 1.44% YoY), while the FY2025 annual figure was $19.5 million, up 1.14% from the prior year.
• Depreciation & Amortization (CF) came in at $4.3 million for Q2 2026 at CRISPR Therapeutics AG, down from $4.3 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $7.3 million in Q2 2022 to a low of $4.3 million in Q2 2026.
• Average Depreciation & Amortization (CF) over 5 years is $5.1 million, with a median of $4.9 million recorded in 2023.
• Year-over-year, Depreciation & Amortization (CF) surged 122.43% in 2022 and slumped 31.75% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $5.8 million in 2022, then declined by 16.18% to $4.9 million in 2023, then slipped by 1.18% to $4.8 million in 2024, then rose by 16.91% to $5.7 million in 2025, then declined by 24.39% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $4.3 million in Q2 2026, $4.3 million in Q1 2026, and $5.7 million in Q4 2025.